Tetravalent Vaccines: The Power of Multivalent E Dimers on Liposomes to Eliminate Immune Interference in Dengue

The Challenge of Dengue Vaccine Development

Dengue virus (DENV) remains one of the most pervasive mosquito-borne viral threats, with its four distinct serotypes (DENV1-4) posing unique immunological challenges. Traditional live-attenuated vaccines have struggled to achieve balanced immunity across all serotypes, often leading to uneven protection and, in some cases, exacerbating disease through antibody-dependent enhancement (ADE). Subunit vaccines, which avoid viral replication entirely, present a promising alternative by allowing precise control over antigen presentation. Recent advances in protein engineering and nanoparticle delivery systems have now unlocked new possibilities for a safer, more effective tetravalent dengue vaccine.

A critical hurdle in dengue immunization is ensuring that the immune response does not favor one serotype over others, as partial immunity can leave individuals vulnerable to severe secondary infections. Live-attenuated vaccines like Dengvaxia have demonstrated this pitfall, where imbalanced responses led to increased hospitalization risks in seronegative recipients. Subunit vaccines circumvent this issue by delivering non-replicating antigens in controlled ratios, but their success hinges on maintaining the structural integrity of key viral proteins—particularly the envelope (E) protein, the primary target of neutralizing antibodies.

The E protein naturally forms dimers on the dengue virion surface, and many potent antibodies recognize quaternary epitopes that span both monomers. However, recombinant E proteins often misfold or remain monomeric, reducing their immunogenicity. Computational stabilization of these dimers has now enabled the production of native-like E protein complexes that preserve critical neutralizing epitopes. When combined with liposomal display systems, these engineered antigens can trigger robust, serotype-specific immunity without the risk of immune interference.

Adjuvanted liposomes, such as those embedded with cobalt-porphyrin phospholipid (CoPoP), enhance immunogenicity by densely arraying antigens on their surface while co-delivering immunostimulatory molecules. This approach not only improves antigen presentation to B cells but also ensures a balanced immune response across multiple serotypes. Recent studies in mice have demonstrated that tetravalent formulations of these liposome-displayed E dimers elicit strong neutralizing antibodies against all four DENV serotypes—without the cross-reactivity that can undermine protection.

The implications of this strategy extend beyond dengue. The same platform could be adapted for other flaviviruses, such as Zika or West Nile virus, where structural preservation of antigens is equally critical. By marrying protein engineering with advanced nanoparticle delivery, researchers are inching closer to a dengue vaccine that avoids the pitfalls of its predecessors—delivering broad, durable protection without the risk of enhancement.

Engineering Stable Dengue E Dimers for Optimal Immunogenicity

The dengue E protein is a metastable structure, prone to dissociation when produced recombinantly. Wildtype soluble E (sE) proteins often fail to form dimers at physiological conditions, diminishing their ability to elicit antibodies against critical quaternary epitopes. To overcome this, researchers have employed computational design to introduce stabilizing mutations at key interfaces—the dimer contact region, the domain I-II hinge, and the core of domain I. These modifications yield E proteins that remain tightly associated as dimers even at low concentrations, closely mimicking their natural conformation on the virion.

Mass photometry analyses confirm that these stabilized E dimers (sE SC) maintain their quaternary structure far more effectively than their wildtype counterparts. While wildtype DENV2, DENV3, and DENV4 sE predominantly exist as monomers, the engineered variants remain dimeric at nanomolar concentrations—a crucial factor for effective antigen presentation. Additionally, these modifications significantly improve protein yield and thermal stability, addressing previous bottlenecks in large-scale vaccine production.

Antibody binding assays further validate the structural integrity of these stabilized dimers. Unlike wildtype sE, which only binds monoclonal antibodies targeting monomeric epitopes, the engineered dimers interact strongly with antibodies that recognize complex, inter-monomer epitopes. This includes well-characterized neutralizing antibodies like B7 and C10, which target the E dimer interface. Importantly, these epitopes remain accessible even after the proteins are conjugated to liposomes, confirming that the display platform does not distort critical antigenic regions.

The enhanced stability and preserved epitope presentation of these engineered dimers translate directly to improved immunogenicity. In murine studies, stabilized E dimers elicit significantly higher neutralizing antibody titers than wildtype sE, particularly when displayed on liposomes. This suggests that both protein engineering and delivery method play synergistic roles in shaping the immune response—ensuring that B cells encounter antigens in their most immunogenic form.

Beyond dengue, this stabilization strategy could be applied to other viral glycoproteins that rely on quaternary structures for immune recognition. The principles of computational protein design, combined with empirical validation, offer a blueprint for optimizing subunit vaccines against complex pathogens where structural fidelity is paramount.

Liposomal Display Enhances Antigen Presentation and B Cell Activation

Adjuvanted liposomes have emerged as a powerful tool for subunit vaccine delivery, combining antigen multivalency with potent immune stimulation. The CoPoP (cobalt-porphyrin phospholipid) liposome platform used in this study serves a dual role: it anchors His-tagged antigens to its surface while co-delivering adjuvants like PHAD-3D6A (a synthetic TLR4 agonist) and QS-21 (a saponin that enhances antibody and T cell responses). This combination creates an immunogenic microenvironment that promotes robust B cell activation and germinal center formation.

Conjugation of dengue E dimers to these liposomes is remarkably efficient, with nearly all proteins binding to the CoPoP moieties within hours. Dynamic light scattering confirms that the liposomes retain their structural integrity post-conjugation, with no signs of aggregation or fusion. This is critical for ensuring consistent antigen presentation in vivo. Once administered, these nanoparticles traffic to lymph nodes, where their dense antigen display mimics the repetitive array of proteins on a viral surface—a key signal for B cell receptor clustering and activation.

Comparative immunization studies in mice reveal that liposomal display significantly enhances the immune response. While soluble E dimers alone can induce neutralizing antibodies, coupling them to CPQ liposomes amplifies both the magnitude and quality of the response. This effect is particularly pronounced for DENV2, where liposome-displayed antigens elicit higher neutralization titers than their soluble counterparts. The adjuvant combination within the liposomes likely synergizes with antigen multivalency to promote stronger germinal center reactions and antibody affinity maturation.

Notably, liposomal display does not distort the antigenic properties of the E dimers. ELISA binding assays confirm that key neutralizing epitopes remain fully accessible after conjugation, ensuring that the immune response is directed against biologically relevant viral structures. This stands in contrast to some traditional vaccine formulations, where adsorption to alum or other carriers can partially obscure critical epitopes.

The flexibility of this platform also allows for precise tuning of antigen ratios in multivalent vaccines. By conjugating each serotype’s E dimers separately before mixing, researchers can ensure balanced presentation of all four DENV serotypes—avoiding the immune dominance issues that plague live-attenuated tetravalent vaccines. This modularity could be extended to other multivalent vaccines, offering a generalizable solution for pathogens with multiple serotypes or variants.

Tetravalent Immunization Elicits Balanced, Type-Specific Neutralizing Responses

A successful dengue vaccine must induce robust immunity against all four serotypes simultaneously, without allowing one response to overshadow the others. Live-attenuated vaccines often fail this balance due to replicative differences between serotypes, but subunit vaccines offer a solution by decoupling immunity from viral fitness. The tetravalent formulation of liposome-displayed E dimers achieves precisely this—eliciting strong, type-specific neutralizing antibodies against DENV1-4 with no evidence of immune interference.

Murine immunization studies demonstrate that the tetravalent CPQ-sE SC formulation generates neutralizing titers against all four serotypes at levels comparable to monovalent or bivalent versions. Remarkably, this balanced response occurs even though each serotype’s antigen dose is halved in the tetravalent mix. This suggests that liposomal display enhances immunogenicity sufficiently to compensate for reduced antigen quantities—a promising finding for clinical translation, where dose-sparing is often critical.

Antibody depletion experiments further confirm the quality of this response. When sera from vaccinated mice are depleted of cross-reactive antibodies, neutralization remains intact unless serotype-matched antigens are removed. This indicates that protection is driven primarily by type-specific antibodies—exactly the response needed to avoid ADE risks. In contrast, many natural dengue infections and some vaccine candidates induce cross-reactive antibodies that offer weak neutralization and may even exacerbate disease.

The absence of immune interference in the tetravalent formulation is particularly noteworthy. Unlike live-attenuated vaccines, where viral competition can skew responses, each liposome-displayed E dimer appears to engage B cells independently. This modularity ensures that introducing additional serotypes does not dilute the response to any single component—a key advantage for achieving uniform protection.

These findings align with broader trends in vaccinology, where nanoparticle-displayed antigens are increasingly recognized for their ability to elicit potent, focused immune responses. For dengue, this approach could finally overcome the historical barriers to a safe, effective tetravalent vaccine—delivering immunity that mirrors natural infection without its attendant risks.

Overcoming Antibody-Dependent Enhancement Through Precision Antigen Design

Antibody-dependent enhancement (ADE) looms large in dengue vaccine development, as suboptimal immunity can turn a second infection into a life-threatening ordeal. ADE occurs when non-neutralizing or cross-reactive antibodies bind to a heterologous serotype, facilitating viral entry into immune cells and amplifying infection. Traditional live-attenuated vaccines risk inducing such antibodies if they fail to generate balanced, type-specific neutralizing responses. Subunit vaccines, by contrast, offer finer control over the antibody repertoire—especially when designed to emphasize structurally authentic epitopes.

The stabilized E dimers used in this study are optimized to elicit antibodies targeting quaternary epitopes, which are often the most potent neutralizers. By preserving these conformational determinants, the vaccine steers the immune response away from non-neutralizing or enhancement-prone antibodies. This is reflected in murine studies, where depletion of cross-reactive antibodies has minimal impact on neutralization—confirming that protection is mediated by type-specific, high-quality antibodies.

Liposomal display further refines this response by promoting B cell activation against densely arrayed, native-like antigens. This mimics the natural context in which B cells encounter viral particles, favoring the selection of antibodies with strong neutralizing potential. The inclusion of adjuvants like PHAD-3D6A and QS-21 also biases the response toward Th1-polarized immunity, which may further reduce ADE risks by limiting the production of weakly neutralizing, cross-reactive antibodies.

The implications for clinical safety are profound. If this approach translates to humans, it could provide the first dengue vaccine that avoids the ADE pitfalls of earlier candidates. By combining structural vaccinology with advanced delivery systems, researchers have created a platform that not only enhances immunogenicity but also minimizes the risk of harmful immune responses.

Beyond dengue, these principles could inform vaccine design for other pathogens where ADE is a concern, such as Zika or respiratory syncytial virus. The ability to precisely control antigen conformation and immune polarization opens new avenues for safer, more effective vaccines—addressing one of the most persistent challenges in infectious disease prevention.

From Murine Models to Human Trials

While murine studies provide compelling proof of concept, dengue’s unique immunopathology necessitates further evaluation in more physiologically relevant models. Non-human primates (NHPs) will be a critical next step, as they permit challenge studies and longer-term immune monitoring—key for assessing durability and protection against heterologous strains. NHP data could also clarify whether the strong type-specific responses observed in mice translate to primates, where pre-existing flavivirus immunity and immune memory dynamics add complexity.

Clinical development will also require optimization of dosing and formulation. The current study uses a 1:4 antigen-to-CoPoP ratio, yielding ~5-6 E dimers per liposome—but fine-tuning this ratio could further enhance immunogenicity or enable dose-sparing. Similarly, adjusting the adjuvant cocktail may help tailor the response for different age groups or populations with varying flavivirus exposure.

Manufacturing scalability is another consideration. The stabilized E dimers show improved yields over wildtype sE, but large-scale production must remain cost-effective for global distribution. Advances in cell-free protein synthesis or plant-based expression systems could further streamline production, making this vaccine accessible in low-resource settings where dengue burden is highest.

If these hurdles are cleared, the liposome-displayed E dimer platform could revolutionize dengue prevention. Its modular design also invites adaptation to other flaviviruses—or even chimeric vaccines targeting multiple pathogens simultaneously. As the first subunit-based tetravalent dengue vaccine to show such balanced, type-specific immunity in preclinical models, this approach represents a major leap toward safer, more effective dengue immunization.

A New Paradigm for Dengue Vaccination

The quest for a safe, effective dengue vaccine has long been hampered by the virus’s immunological complexity. Live-attenuated vaccines, while advanced, struggle to achieve balanced tetravalent immunity—often falling short or, worse, increasing disease risk in some recipients. The liposome-displayed E dimer platform circumvents these challenges by delivering precise, non-replicating antigens in their most immunogenic form.

By combining computational protein design with nanoparticle delivery, this strategy elicits robust, type-specific neutralizing antibodies against all four DENV serotypes—without immune interference or ADE-prone cross-reactivity. Its success in murine models paves the way for further development, offering hope for a vaccine that finally meets dengue’s global threat head-on. Beyond dengue, the principles established here could inform next-generation vaccines for other complex pathogens, marking a turning point in structural vaccinology.

The road ahead will require rigorous clinical validation, but the foundation is solid. For the first time, a dengue vaccine candidate has demonstrated the elusive trifecta of broad coverage, balanced immunity, and minimal enhancement risk—bringing us closer than ever to a world where dengue’s scourge is consigned to history.

Study DOI: https://doi.org/10.1038/s41541-025-01179-w

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES